Robert H. Lenox

Dr. Lenox has had a distinguished academic research and teaching career for over 25 years as a respected psychiatrist and neuroscientist with continuous NIH grant funding and more than 150 peer-reviewed publications, as well as reviews and book chapters, in the fields of molecular neuropharmacology and clinical psychopharmacology. He is also the recipient of numerous prestigious awards and honors that recognize his contributions to medicine, including the NARSAD Distinguished Investigator Award, Editor-in-Chief of Neuropsychopharmacology, Life Fellow of the American College of Neuropsychopharmacology, and Distinguished Fellow of the American Psychiatric Association.

Dr. Lenox is currently providing CNS drug discovery and development consultation to Academia, Biotech and Venture Capital companies. Until recently he served as Vice President and Worldwide Head of Central Nervous System Drug Discovery for Sanofi- Aventis Pharmaceuticals, with responsibilities for setting strategy and leading CNS drug discovery from target identification, lead discovery and candidate profiling, with oversight for preclinical/phase l and ll development at Aventis for all psychiatry and neurology programs. Prior to entering the pharmaceutical industry in 2001, Dr. Lenox was the Karl and Linda Rickels Professor of Psychiatry, Pharmacology and Neuroscience and Vice Chairman for Research Development in the Department of Psychiatry at the University of Pennsylvania School of Medicine. Dr. Lenox was also Founder of the Neuroscience Research Unit and Head of the Clinical Psychopharmacology Program in the Department of Psychiatry at the University of Vermont College of Medicine, where he also served as Interim-Chairman.

Education

M.D.

University of Vermont College of Medicine

M.A.

University of Pennsylvania Perelman School of Medicine

B.S.

Massachusetts Institute of Technology

Board Certifications and Licenses

Diplomate, American Board of Psychiatry and Neurology

Expertise

CNS drug discovery and development for both psychiatric and neurological disorders; molecular neuropharmacology and clinical psychopharmacology

Research

Research Interests

·   CNS drug discovery and development for both psychiatric and neurological disorders
·   Molecular neuropharmacology
·   Clinical psychopharmacology

Selected Publications

Belmaker, R.H., Agam, G., and Lenox, R.H. Neurobiology and Pharmacotherapy of Bipolar Disorder. In: Handbook of Contemporary Neuropharmacology. Sibley, D. (Ed). John Wiley and Sons, Inc., 2007, Vol. 1; Chapter 22; Pp. 859-875.

McNamara, R. K., Hussain, R.J., Simon, E.J.,  Stumpo, D.J., Blackshear, P.J., Abel, T., Lenox, R.H., Effect of Myristoylated Alanine Rich C Kinase Substrate (MARCKS) Overexpression on Hippocampus-Dependent Learning and Hippocampal Synaptic Plasticity in MARCKS Transgenic Mice. Hippocampus 15:675-683, 2005.

Lenox, R.H. and Wang, L. Molecular basis of lithium action: Integration of lithium-responsive signaling and gene expressions networks.  Molecular Psychiatry.  8(2);135-144.  2003.

Lenox, R. H., Gould, T.D., Manji, H. K.  Endophenotypes in bipolar disorder. Am J. Med. Genet. 114(4):391-406, 2002.

Lenox, R.H. and Frazer, A. Mechanism of Action of Antidepressants and Mood-Stabilizers.  In Neuropsychopharmacology: The Fifth Generation of Progress.  Charney, D., Coyle, J., Davis, K., Nemeroff, C. (eds). Lippincott Williams & Wilkins. 2002, Chapter 79; Pp. 1139-1163.

Yarmola, E.G., Edison, E.S., Lenox, R.H., and Bubb, M.R. Actin filament cross-linking by MARCKS: Characterization of two actin-binding sites within the phosphorylation domain. J Biol. Chem  276(25):22351-8, 2001.

Manji, H. K., and Lenox, R. H. Signaling: Cellular insights into the pathophysiology of bipolar disorder. Biol Psychiatry  48(6):518-530, 2000.

Potter, A., Corwin, J., Lang, J., Lenox, R.H., and Newhouse, P.A. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 improved learning in AlzheimerÕs Disease. Psychopharmacology 142:334-342, 1999.

McNamara, R. K., Stumpo, D. J., Lewis, M. H., Morel, L. M., Wakeland, E. K., Blackshear, P. J. and Lenox, R. H. Effects of alterations in MARCKS expression on spatial learning in mutant mice: transgenic rescue and interaction with gene background. Proc Natl Acad Sci U.S.A., 95:14517-14522, 1998.

Research Topics

Robert Lenox

Robert H. Lenox

,

M.D.

Professor of Pharmacology and Clinical Neuroscience; President, RHL Consulting, LLC, Biopharmaceutical CNS Drug Discovery and Development

Biddeford Campus

Off-Campus
Stella Maris 331

rlenox@une.edu

(207) 602-2336

On Campus